[
  {
    "ts": null,
    "headline": "Why the Market Dipped But Merck (MRK) Gained Today",
    "summary": "Merck (MRK) closed at $108.34 in the latest trading session, marking a +1.35% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=0863bf1e10bb5bace33a0cfb6b8c286e631c6ad8cee4dd32ce4ae05b17bb7b0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769727002,
      "headline": "Why the Market Dipped But Merck (MRK) Gained Today",
      "id": 138302016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) closed at $108.34 in the latest trading session, marking a +1.35% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=0863bf1e10bb5bace33a0cfb6b8c286e631c6ad8cee4dd32ce4ae05b17bb7b0d"
    }
  },
  {
    "ts": null,
    "headline": "Merck Ends Revolution Talks Leaving Capital Allocation And Valuation In Focus",
    "summary": "Merck (NYSE:MRK) has ended acquisition talks with oncology-focused Revolution Medicines. The discussions centered on a potential multi billion dollar deal that had drawn wide industry attention. The decision halts one of the higher profile biotech M&A conversations currently on investors’ radar. Merck is a large pharmaceutical group with a significant presence in oncology, vaccines, and specialty therapies, and has been active in partnerships to support its drug pipeline. The halted talks...",
    "url": "https://finnhub.io/api/news?id=3c98547b5b447f226b7e471ec6d2635f5842a07b7ecfc9f8956e6a5171c4cf9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769703076,
      "headline": "Merck Ends Revolution Talks Leaving Capital Allocation And Valuation In Focus",
      "id": 138297182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) has ended acquisition talks with oncology-focused Revolution Medicines. The discussions centered on a potential multi billion dollar deal that had drawn wide industry attention. The decision halts one of the higher profile biotech M&A conversations currently on investors’ radar. Merck is a large pharmaceutical group with a significant presence in oncology, vaccines, and specialty therapies, and has been active in partnerships to support its drug pipeline. The halted talks...",
      "url": "https://finnhub.io/api/news?id=3c98547b5b447f226b7e471ec6d2635f5842a07b7ecfc9f8956e6a5171c4cf9c"
    }
  },
  {
    "ts": null,
    "headline": "Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.",
    "url": "https://finnhub.io/api/news?id=1c208a0cdf1a8b2f4922eebe045529fbeac1ffe6c75f9d1e058a7277534032c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769696107,
      "headline": "Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics",
      "id": 138295653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.",
      "url": "https://finnhub.io/api/news?id=1c208a0cdf1a8b2f4922eebe045529fbeac1ffe6c75f9d1e058a7277534032c0"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=5a59d0cc9e95dc089412dacb04c326c86ebaf9dd540780907590636afa7f0949",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769695206,
      "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 138297183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=5a59d0cc9e95dc089412dacb04c326c86ebaf9dd540780907590636afa7f0949"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A High-Yield Pharma At A Turning Point",
    "summary": "Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=ea773c0df2a52f5a28c6fe2da838c9ea509d4f6789a120078f8d1a8b0101e264",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769677200,
      "headline": "Pfizer: A High-Yield Pharma At A Turning Point",
      "id": 138295067,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202955977/image_1202955977.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=ea773c0df2a52f5a28c6fe2da838c9ea509d4f6789a120078f8d1a8b0101e264"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks to Target This Week and 1 We Ignore",
    "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
    "url": "https://finnhub.io/api/news?id=9b3f753920abc8bbe1d9a8b57aa07eda4f55d0367c83a0885728fabe29ed0841",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769661132,
      "headline": "2 Cash-Producing Stocks to Target This Week and 1 We Ignore",
      "id": 138298536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
      "url": "https://finnhub.io/api/news?id=9b3f753920abc8bbe1d9a8b57aa07eda4f55d0367c83a0885728fabe29ed0841"
    }
  }
]